A 38-year-old woman from Delhi presents to the emergency department with a 3-day history of high fever (39.8°C), severe myalgia, headache, and dry cough. She reports that her 12-year-old son had similar symptoms 5 days ago. On examination, she is febrile but alert, with clear lungs and no focal findings. A rapid antigen test for influenza A is positive. She has no significant past medical history and is not on any medications. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Diagnosis and Management of Influenza A ### Key Clinical Features **Key Point:** This patient presents with classic influenza syndrome — acute onset fever, myalgia, headache, and respiratory symptoms in the context of a household cluster (son affected 5 days prior). The positive rapid antigen test confirms influenza A. ### Timing and Antiviral Therapy **High-Yield:** Neuraminidase inhibitors (oseltamivir) are most effective when started within 48 hours of symptom onset. This patient is at day 3, but treatment is still indicated because: - Early treatment reduces symptom duration by 1–2 days - Reduces risk of complications (secondary bacterial pneumonia, hospitalization) - Reduces viral shedding and transmission - Standard dose: oseltamivir 75 mg orally twice daily for 5 days ### Why This Patient Does NOT Require Hospitalization or Intensive Intervention **Clinical Pearl:** Uncomplicated influenza in an immunocompetent adult with normal oxygen saturation and no respiratory distress does not require: - Admission - Mechanical ventilation - Ribavirin (reserved for severe cases, immunocompromised patients, or pandemic strains) - Empiric antibiotics (no clinical or radiological evidence of secondary bacterial infection) ### Diagnostic Confirmation **Key Point:** A positive rapid antigen test in a symptomatic patient with epidemiological context (household cluster) is sufficient to initiate treatment. Repeat testing is unnecessary and delays therapy. ### Summary Table: Antiviral Agents for Influenza | Agent | Mechanism | Indication | Timing | Dose | | --- | --- | --- | --- | --- | | Oseltamivir | Neuraminidase inhibitor | Uncomplicated influenza | Within 48 hrs (but still effective up to 5 days) | 75 mg PO BD × 5 days | | Zanamivir | Neuraminidase inhibitor | Alternative if oseltamivir resistance | Within 48 hrs | 5 mg inhaled BD × 5 days | | Peramivir | Neuraminidase inhibitor | IV option (severe/unable to take PO) | Within 48 hrs | 600 mg IV once | | Baloxavir | Cap-dependent endonuclease inhibitor | Single-dose option | Within 48 hrs | 40–80 mg PO once | [cite:Harrison 21e Ch 195]